Photo from wikipedia
Apalutamide (Erleada) is a selective androgenreceptor inhibitor licensed for the treatment of nonmetastatic castrationresistant prostate cancer in men who are at high risk of developing metastatic disease. This article discusses… Click to show full abstract
Apalutamide (Erleada) is a selective androgenreceptor inhibitor licensed for the treatment of nonmetastatic castrationresistant prostate cancer in men who are at high risk of developing metastatic disease. This article discusses its properties, efficacy and side‐effects.
Keywords:
apalutamide treatment;
treatment;
treatment non;
prostate cancer
Journal Title: Prescriber
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Prescriber
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!